such a hypothesis, the sampling strategy (undiagnosed controls) could have reduced the power of our case/control analysis since major depression demonstrates a prevalence of 5-17%. Accordingly, this could partially explain the modest haplotypic association. In conclusion, owing to the potential role of TPH in affective disorders, and the restricted expression of the TPH2 isoform in brain, the results reported, together with those of Zill et al, clearly show the need for further investigations. SIR-AKT1 is a serine/threonine kinase known as protein kinase B. Modulation of AKT1 activity appears to play a key role in the mechanism of glutamate excitotoxicity and lithium neuroprotection. 1 Glycogen synthase kinase 3b (GSK3b) is one of the substrates of AKT1 and AKT1/GSK3b signaling is known as a target of lithium. Lithium can exert its acute effect on dopamine-dependent behaviors by interfering with the action of dopamine on an Akt/ GSK-3 signaling cascade in the brain of living mice.
Failure to confirm association between AKT1 haplotype and schizophrenia in a Japanese case-control population SIR-AKT1 is a serine/threonine kinase known as protein kinase B. Modulation of AKT1 activity appears to play a key role in the mechanism of glutamate excitotoxicity and lithium neuroprotection. 1 Glycogen synthase kinase 3b (GSK3b) is one of the substrates of AKT1 and AKT1/GSK3b signaling is known as a target of lithium. Lithium can exert its acute effect on dopamine-dependent behaviors by interfering with the action of dopamine on an Akt/ GSK-3 signaling cascade in the brain of living mice. 2 Transmission of haplotypes construct from seven single-nucleotide polymorphisms (SNPs) in a highly variable region of the AKT1 gene has been shown to have a weak evidence of association with bipolar disorder. 3 Recently, Emamian et al 4 identified AKT1 as a potential schizophrenia susceptibility gene in families of northern European origin. Levels of the AKT1 protein and phosphorylation of GSK3b at Ser9 in lymphocytes and frontal cortex were significantly lower in patients with schizophrenia in comparison with the controls. Moreover, AKT1-deficient mice treated with amphetamine show reduced prepulse inhibition (PPI). The impairment of PPI has been observed in patients with schizophrenia. Haloperidol-treated mice show increased phosphorylation of GSK3b at Ser9. In multi-SNP haplotype analysis, haplotypes containing two to five SNPs (SNP1-5) in the AKT1 gene were associated with schizophrenia. The TCG haplotype consisting of three SNPs (SNP2/ 3/4) showed the highest significant association with schizophrenia (ratio of transmission to no transmission ¼ 1.8, P ¼ 0.0006). The AKT1 core risk haplotype TC of the SNP2/3 is associated with lower AKT1 protein levels.
We attempted to confirm the association of AKT1 haplotype with schizophrenia in Japanese subjects comprising of 559 patients with schizophrenia and 567 controls. All subjects were unrelated. The TCG haplotype was estimated to confer a relative risk of 1.9 in the study by Emamian et al. 4 Our sample size has 0.999 power to detect the association at the haplotype frequency of 0.085, which was observed in our Japanese control subjects, at a nominal significance level of 5%.
The patients with schizophrenia analyzed were 559 unrelated Japanese (320 men, 239 women; age 18-90 years, mean 49.5 years). Diagnoses were determined after unstructured clinical interviews, and final diagnoses were carried out by consensus of at least two psychiatrists. All subjects met DSM-III-R criteria for schizophrenia. The control subjects consisted of 567 unrelated Japanese individuals (390 men, 177 women; age 29-77 years, mean 51.6 years). Control subjects were not evaluated by psychiatrists. Written informed consent was obtained from all subjects. This study was approved by the Ethics Committees of University of Tsukuba, Tokyo Medical and Dental University, the National Center of Neurology and Psychiatry, and Nagoya University. We examined the population structure with Structure software (http:// pritch.bsd.uchicago.edu/) 5 to rule out the possibility that the difference in a case-control study was influenced by hidden population stratification. We genotyped 32 markers (seven microsatellite markers and 25 SNPs) and observed no subpopulation using the number of assumed subpopulation k ¼ 2 and 3 (data not shown).
The ID numbers of these five SNPs were provided by Emamian et al. 4 All SNPs were genotyped with Taqman s Assays-by-Design SM SNP Genotyping Service (Applied Biosystems) 6 and ABI PRISM s 7900HT Sequence Detection System (Applied Biosystems). Upper: global P-value (uncorrected), lower: haplotype-specific permutation P-value.
The haplotype-specific P-value of the core risk haplotype (TC for SNP2/3) reported by Emamian et al 4 was 0.347 and the haplotype frequencies were 0.141 in the patients and 0.154 in the controls. The haplotype-specific P-value of the highest significant haplotype (TCG for SNP2/3/4) reported by Emamian et al 4 was 0.848 and the haplotype frequencies were 0.087 in the patients and 0.085 in the controls. Chromosome position was referred to dbSNP database.
Scientific Correspondence
Tests for single-marker allelic association were performed by w 2 analysis. Haplotype was estimated with an expectation-maximization (EM) algorithm. Tests for haplotypic association were performed with COCAPHASE software (http://www.hgmp.mrc.ac.uk/ fdudbrid/software/unphased/). 7 Haplotypes with frequencies less than 3% were regarded as rare. Pairwise linkage disequilibrium (LD) was calculated with GOLD software (http://www.sph.umich.edu/ csg/abecasis/GOLD/index.html). 8 The genotypic distributions of the five SNPs did not deviate from Hardy-Weinberg equilibrium in both groups. Pairwise LD between adjacent SNPs was similar to those reported by Emamian et al 4 ( Table 1) . We found no association between each SNP and schizophrenia ( Table 1 ). The frequency of the core risk haplotype (TC for SNP2/3) did not differ significantly between patients with schizophrenia (0.141) and controls (0.154) in our Japanese samples. Furthermore, the frequency of the highest significant haplotype (SNP2/ 3/4, TCG) by Emamian et al 4 did not differ between patients with schizophrenia (0.087) and controls (0.085) in our Japanese samples (odds ratio 1.03, 95% confidence interval 0.76-1.38) ( Table 1) . Significant associations were not detected between other haplotypes and patients with schizophrenia (Table 1) . We further performed stratified analysis of the data by age at onset, familial loading, and sex. No significant associations were observed (data not shown).
In the present study, we could not confirm the association between AKT1 haplotype and schizophrenia in our Japanese samples. The TCG haplotype frequency was lower in our Japanese population (0.085) than in populations of northern European origin (0.15). The power of this study to detect an association in our Japanese population is sufficient even at the haplotype frequency of 0.085; however, the different ethnical background may preclude confirmation of the genetic association. Haplotype construction is less reliable in population-based samples than in family-based samples; therefore, haplotype estimation procedure of the present study might make confirmation of the genetic association difficult. Furthermore, the samples examined by Emamian et al 4 included 210 proband-parent triads and 58 extended families with multiple affected individuals obtained from the NIMH Genetics Initiative. Although the w 2 test did not show a significant difference in either allelic or haplotypic frequencies between 92 patients with first-degree relatives who had schizophrenia and controls (data not shown), it remains possible that the association is observed only in familial schizophrenia. Finally, we cannot exclude the existence of a weak association because the 95% confidence interval of the odds ratio was 0.76-1.38 in our population.
